GALACTIC-1 A Randomized, Double-blind, Multicentre, Parallel, Placebo-controlled Phase 2b Study in Subjects With Idiopathic Pulmonary Fibrosis Investigating the Efficacy and Safety of TD139, an Inhaled Galectin-3 Inhibitor Administered Via Dry Powder Inhaler Over 52 Weeks
Phase of Trial: Phase II
Latest Information Update: 03 Dec 2019
Price : $35 *
At a glance
- Drugs TD 139 (Primary) ; Nintedanib; Pirfenidone
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Acronyms GALACTIC-1
- Sponsors Galecto Biotech
- 20 Feb 2019 Status changed from not yet recruiting to recruiting.
- 05 Feb 2019 Status changed from planning to not yet recruiting.
- 01 Nov 2018 New trial record